Published in J Clin Invest on February 01, 2004
Cardiovascular protection by ApoE and ApoE-HDL linked to suppression of ECM gene expression and arterial stiffening. Cell Rep (2012) 1.34
Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall. J Lipid Res (2008) 1.18
Apolipoprotein E inhibition of vascular hyperplasia and neointima formation requires inducible nitric oxide synthase. J Lipid Res (2005) 0.98
Structure-function properties of the apoE-dependent COX-2 pathway in vascular smooth muscle cells. Atherosclerosis (2007) 0.92
ApoE promotes hepatic selective uptake but not RCT due to increased ABCA1-mediated cholesterol efflux to plasma. J Lipid Res (2012) 0.89
Glycosylation and sialylation of macrophage-derived human apolipoprotein E analyzed by SDS-PAGE and mass spectrometry: evidence for a novel site of glycosylation on Ser290. Mol Cell Proteomics (2010) 0.87
Type VIII collagen mediates vessel wall remodeling after arterial injury and fibrous cap formation in atherosclerosis. Am J Pathol (2013) 0.84
Scavenger receptor class B, type I (Scarb1) deficiency promotes osteoblastogenesis but stunts terminal osteocyte differentiation. Physiol Rep (2014) 0.81
Apolipoprotein E gene polymorphism and serum lipid profile in Saudi patients with psoriasis. Dis Markers (2014) 0.81
Apolipoprotein E-mediated cell cycle arrest linked to p27 and the Cox2-dependent repression of miR221/222. Atherosclerosis (2012) 0.80
Cyclooxygenase products and atherosclerosis. Drug Discov Today Ther Strateg (2008) 0.79
Apolipoprotein E3 Inhibits Rho to Regulate the Mechanosensitive Expression of Cox2. PLoS One (2015) 0.79
apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL. J Lipid Res (2014) 0.75
High-density lipoprotein: a novel target for antirestenosis therapy. Clin Transl Sci (2014) 0.75
Concern Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med (2000) 29.03
Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science (1988) 13.54
Cyclooxygenase in biology and disease. FASEB J (1998) 7.17
Human endothelial cells: use of heparin in cloning and long-term serial cultivation. Science (1983) 6.44
Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev (2000) 6.07
Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A (1992) 5.21
Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev (1995) 4.94
Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (2002) 4.59
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A (1999) 4.16
Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A (1996) 3.93
Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J Cell Biol (1996) 2.56
The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J Clin Invest (2001) 2.04
Cell cycle regulation of cyclin A gene expression by the cyclic AMP-responsive transcription factors CREB and CREM. Mol Cell Biol (1995) 1.96
The adenovirus EIIA enhancer. Analysis of regulatory sequences and changes in binding activity of ATF and EIIF following adenovirus infection. J Biol Chem (1989) 1.93
Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes. FASEB J (1993) 1.90
COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov (2003) 1.82
Alpha5beta1 integrin controls cyclin D1 expression by sustaining mitogen-activated protein kinase activity in growth factor-treated cells. Mol Biol Cell (1999) 1.73
p107 and p130: versatile proteins with interesting pockets. Exp Cell Res (2001) 1.73
Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev (1994) 1.62
Prostaglandin E2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent. Am J Respir Cell Mol Biol (2002) 1.47
Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem (1994) 1.45
Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene (1999) 1.31
Lipid binding-induced conformational change in human apolipoprotein E. Evidence for two lipid-bound states on spherical particles. J Biol Chem (2001) 1.31
Apolipoprotein E inhibits platelet-derived growth factor-induced vascular smooth muscle cell migration and proliferation by suppressing signal transduction and preventing cell entry to G1 phase. J Biol Chem (1998) 1.26
Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest (1999) 1.25
Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J Biol Chem (2001) 1.23
Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. Br J Cancer (1999) 1.22
Apolipoprotein-mediated plasma membrane microsolubilization. Role of lipid affinity and membrane penetration in the efflux of cellular cholesterol and phospholipid. J Biol Chem (1999) 1.19
Rapid regression of atherosclerosis induced by liver-directed gene transfer of ApoE in ApoE-deficient mice. Arterioscler Thromb Vasc Biol (1999) 1.16
Apolipoprotein E inhibition of vascular smooth muscle cell proliferation but not the inhibition of migration is mediated through activation of inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol (2000) 1.16
Apolipoprotein E inhibits neointimal hyperplasia after arterial injury in mice. Am J Pathol (2000) 1.12
Inhibition of PDGF-stimulated and matrix-mediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin-dependent kinase inhibitors. J Cell Biochem (2002) 1.08
HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (Cox-2). Arterioscler Thromb Vasc Biol (1997) 1.05
Prostacylin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin a gene expression. Mol Pharmacol (2003) 0.99
Antiproliferative properties of sphingosine 1-phosphate in human hepatic myofibroblasts. A cyclooxygenase-2 mediated pathway. J Biol Chem (2000) 0.98
Apolipoprotein E receptor binding versus heparan sulfate proteoglycan binding in its regulation of smooth muscle cell migration and proliferation. J Biol Chem (2001) 0.95
Shear stress induces transforming growth factor-beta 1 release by arterial endothelial cells. Surgery (1998) 0.94
Distinct effects of mitogens and the actin cytoskeleton on CREB and pocket protein phosphorylation control the extent and timing of cyclin A promoter activity. Mol Cell Biol (2001) 0.91
Apolipoprotein E inhibits serum-stimulated cell proliferation and enhances serum-independent cell proliferation. J Biol Chem (2001) 0.90
Stimulation of vascular smooth muscle cell prostacyclin and prostaglandin E2 synthesis by plasma high and low density lipoproteins. Circ Res (1984) 0.90
Adenosine 3':5'-cyclic monophosphate induces regulated secretion of tissue-type plasminogen activator and von Willebrand factor from cultured human endothelial cells. Thromb Haemost (1998) 0.89
Prostacyclin and the vascular endothelium. Bull Eur Physiopathol Respir (1981) 0.87
Perlecan mediates the antiproliferative effect of apolipoprotein E on smooth muscle cells. An underlying mechanism for the modulation of smooth muscle cell growth? J Biol Chem (1999) 0.87
High-density-lipoprotein-induced cholesterol efflux from arterial smooth muscle cell derived foam cells: functional relationship of the cholesteryl ester cycle and eicosanoid biosynthesis. Biochemistry (1990) 0.86
Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells. Oncogene (2002) 0.82
Cloning and expression of activator of CREM in testis in human testicular tissue. Biochem Biophys Res Commun (2001) 0.80
Eicosanoid biosynthesis in human cardiovascular disease. Hum Pathol (1987) 0.80
Heparinase III limits rat arterial smooth muscle cell proliferation in vitro and in vivo. Eur J Pharmacol (1998) 0.80
Regulatory effects of HDL on smooth muscle cell prostacyclin release. Arterioscler Thromb Vasc Biol (1999) 0.80
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet (2006) 19.03
A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science (2007) 18.96
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med (2011) 13.55
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet (2007) 13.28
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature (2010) 12.07
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med (2003) 9.23
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol (2008) 7.86
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One (2008) 7.16
Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet (2009) 6.83
The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet (2008) 6.72
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet (2007) 5.88
A functional genomics strategy reveals Rora as a component of the mammalian circadian clock. Neuron (2004) 5.71
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol (2011) 4.67
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (2002) 4.59
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest (2006) 4.50
New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res (2005) 4.47
A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet (2005) 4.45
Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med (2009) 4.45
NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem (2004) 4.37
Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet (2008) 4.31
Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest (2007) 4.20
Resolution of lung inflammation by CD44. Science (2002) 4.09
Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol (2010) 4.08
Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07
Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med (2010) 3.73
Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med (2007) 3.70
Resistin is an inflammatory marker of atherosclerosis in humans. Circulation (2005) 3.52
Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice. Arterioscler Thromb Vasc Biol (2002) 3.51
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med (2004) 3.49
Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation (2006) 3.49
Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation (2012) 3.38
The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med (2004) 3.34
Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol (2003) 3.26
Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation (2005) 3.25
Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation (2003) 3.24
The metabolic syndrome: more than the sum of its parts? Circulation (2003) 3.22
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol (2010) 3.20
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A (2011) 3.14
Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project. PLoS Genet (2011) 3.07
Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med (2003) 2.98
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Candidate gene association resource (CARe): design, methods, and proof of concept. Circ Cardiovasc Genet (2010) 2.91
COX-2-derived prostacyclin confers atheroprotection on female mice. Science (2004) 2.87
Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet (2009) 2.85
Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation (2003) 2.77
Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation (2012) 2.76
Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol (2003) 2.70
Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation (2003) 2.69
Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest (2009) 2.66
Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. J Lipid Res (2005) 2.61
Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles. J Biol Chem (2007) 2.53
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res (2008) 2.51
An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med (2004) 2.51
CPAP, weight loss, or both for obstructive sleep apnea. N Engl J Med (2014) 2.50
Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest (2005) 2.47
Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol (2008) 2.41
The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res (2007) 2.38
Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression. J Clin Invest (2011) 2.37
Cell-cycle control by physiological matrix elasticity and in vivo tissue stiffening. Curr Biol (2009) 2.37
Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA (2003) 2.32
Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J Clin Invest (2003) 2.27
Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis (2011) 2.25
High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol (2010) 2.23
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
Characterization of the lipolytic activity of endothelial lipase. J Lipid Res (2002) 2.16
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
Statins and cognitive function: a systematic review. Ann Intern Med (2013) 2.10
Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem (2007) 2.10
A genome-wide association study reveals variants in ARL15 that influence adiponectin levels. PLoS Genet (2009) 2.09
Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol (2005) 2.08
Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer. Hum Pathol (2013) 2.06